⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 15, 2024Future Medicinal Chemistry

Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2

Yong Yan Hanwen Liu Di Wu Zhihao Gu Wenhao Guo Hequan Yao Kejiang Lin Xuanyi Li

View Full Paper

Ask AI

Bookmark

Share

Abstract

The epidemic caused by SARS-CoV-2 swept the world in 2019. The 3C-like protease (3CLpro) of SARS-CoV-2 plays a key role in viral replication, and its inhibition could inhibit viral replication.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yan et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2a2b6db64358766cffa https://doi.org/10.4155/fmc-2024-0015

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Structure-Based Optimization and Biological Evaluation of SARS-CoV-2 3CLpro Covalent Inhibitors2024
2Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-22024 · 3 citations
3Exploring New Small Molecule Inhibitors for SARS‐CoV‐2 3CLpro: A Comprehensive Computational Study2024 · 3 citations
4Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-22024 · 1 citations
53-Chymotrypsin-like Protease (3CLpro): Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials2024 · 2 citations